ANTI — Antigenics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -478.9% | ||
| Return on Equity | -316.03% | ||
| Operating Margin | -784.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 1996 | 1997 | 1998 | 1999 | 2000 | 2001E | 2002E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.67 | 0.84 | 6.74 | 11.05 | 3.22 | n/a | n/a | 20.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Antigenics Inc., formerly Agenus Inc., is an immunotherapy company. The Company is developing a series of checkpoint modulators (CPM) for the treatment of patients with cancer, infectious diseases, and other immune disorders; heat shock protein (HSP)-based vaccines, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Retrocyte Display (Retroviral B Lymphocyte Display) is an antibody discovery platform designed for the discovery and optimization of fully human and humanized monoclonal antibodies against an array of molecular targets. Its HSP-based vaccine platform includes its Prophage Series vaccine candidates for the treatment of cancer and its HerpV vaccine candidate for the treatment of genital herpes. Its pipeline of product candidates containing QS-21 Stimulon includes vaccines for infectious diseases, cancer types and Alzheimer's disease.
Directors
- Last Annual
- December 31st, 2000
- Last Interim
- March 31st, 2001
- Incorporated
- January 1st, 1970
- Public Since
- July 18th, 2001
- No. of Shareholders
- 6,100
- No. of Employees
- 29
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 341,662,538
- Address
- 700 Business Center Dr, HORSHAM, 19044
- Web
- Phone
- +1 2154415400
- Auditors
- Arthur Andersen LLP
Similar to ANTI
Acacia Diversified Holdings
Pink Sheets on Nasdaq
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
FAQ
As of Today at 19:02 UTC, shares in Antigenics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Antigenics last closed at $0.00 and the price had moved by +600% over the past 365 days. In terms of relative price strength the Antigenics share price has outperformed the S&P500 Index by +517.59% over the past year.
There is no consensus recommendation for this security.
Antigenics does not currently pay a dividend.
Antigenics does not currently pay a dividend.
Antigenics does not currently pay a dividend.
To buy shares in Antigenics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Antigenics had a market capitalisation of .
Here are the trading details for Antigenics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ANTI
Based on an overall assessment of its quality, value and momentum Antigenics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Antigenics. Over the past six months, its share price has underperformed the S&P500 Index by -93.97%.
As of the last closing price of $0.00, shares in Antigenics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Antigenics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Antigenics' directors